Rheumatology Advance Access originally published online on August 19, 2009
Rheumatology 2009 48(10):1294-1299; doi:10.1093/rheumatology/kep200
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Effect of a second, booster, influenza vaccination on antibody responses in quiescent systemic lupus erythematosus: an open, prospective, controlled study
1Department of Rheumatology and Clinical Immunology, 2Division of Infectious Diseases, Department of Internal Medicine, 3Department of Medical Microbiology, Molecular Virology Section, University Medical Center Groningen, University of Groningen, 4Laboratory for Infectious Diseases, Groningen and 5Solvay Pharmaceuticals, Weesp, The Netherlands
Correspondence to: Albert Holvast, Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands. E-mail: b.holvast{at}int.umcg.nl
 |
Abstract |
|---|
Objective. In SLE, a decreased antibody response on influenza vaccination has been reported. In this study, we assessed whether a booster vaccination could improve antibody responses, as determined by seroprotection rates, in SLE patients.
Methods. SLE patients (n = 52) with quiescent disease (SLEDAI 
4) and healthy controls (HCs) (n = 28) received subunit influenza vaccine in October–December 2007. After 4 weeks, only SLE patients received a second dose of vaccination. Sera were obtained before both vaccinations, and 4 weeks after the second vaccination. At each visit, SLE disease activity was recorded. The haemagglutination inhibition test was used to measure antibody titres. Seroprotection was defined as a titre 
40.
Results. Following the first vaccination, seroprotection rates and geometric mean titres (GMTs) to each vaccine strain increased in both SLE patients and controls to comparable levels. Seroprotection rates in SLE patients after the first vaccination were 86.5% to A/H1N1, 80.8% to A/H3N2 and 61.5% to the B-strain while GMTs were 92.6, 56.2 and 39.2, respectively. Overall, the booster vaccination did not lead to a further rise of seroprotection rates and GMTs in SLE patients. However, in patients not vaccinated in the previous year, GMT and seroconversion rate to A/H1N1 did rise following the booster vaccination. Both influenza vaccinations did not increase SLEDAI scores.
Conclusions. Additional value of a booster influenza vaccination in SLE is limited to patients who were not vaccinated in the previous year.
KEY WORDS: Systemic lupus erythematosus, Influenza vaccination, Booster vaccination, Antibody responses
Submitted 9 March 2009;
revised version accepted 9 June 2009.
CiteULike 
Connotea 
Del.icio.us What's this?